RP-1920 BioRadon

PROJECT DESCRIPTION

The Bioradon – EORTC 1920 LCC – project will assess the correlation between the molecular profiles of NSCLC patients and radon exposure.

Pr. Benjamin Besse,
Pr. Benjamin Besse,Gustave Roussy(France)
Dr. Laura Mezquita,
Dr. Laura Mezquita,Hospital Clinic Universitari de Barcelona(Spain)

A radon detector will measure the in-house radon concentration. A report with the radon concentration will be shared with the treated clinician.

Patient with non-small cell lung cancer could be eligible for this project.

List of cohort

A blood tube is mandatory for inclusion in this project and a FFPE sample is optional.

The project has received funding from the Euratom research and training programme 2019-2020 under grant agreement No 900009 (Radonorm project), Novartis, Ely Lilly, Beigene, Aureus Ars & Scientia and the EORTC Lung Cancer Group. For more information on the project, please contact the project team 1920@eortc.org.

LIST OF COHORTS

For SPECTA, please enroll patients with the tumor type specified in the table, ONLY when the status is green. You can enroll those patients by clicking on the , next to the green status.
Study specific information (HBM, Project Specific selection criteria, CRF completion guidelines…) can be found here . Please note that your electronic database ORTA password is required for access (protocol 1553).

For any questions, please contact the project e-mail address: 1920@eortc.org.

To view the List of Cohorts, please flip your mobile phone horizontally:

Primary disease Status
Cohort 3: NSCLC patients, currently living in the same home and for at least 2 years prior to NSCLC diagnosis and at any stage of disease, including:

  • Newly diagnosed patients,
  • Patients under treatment for early, locally, or advanced disease
  • Patients under follow-up
  • Survivors (if treatment received within 5 years of inclusion in SPECTA), and
  • presenting a driver mutation: EGFR, BRAFV600, MET, HER2
 Open to activated sites
Cohort 4: NSCLC patients, currently living in the same home and for at least 2 years prior to NSCLC diagnosis and at any stage of disease, including:

  • Newly diagnosed patients,
  • Patients under treatment for early, locally, or advanced disease
  • Patients under follow-up
  • Survivors (if treatment received within 5 years of inclusion in SPECTA), and
  • presenting a driver fusion (ALK, ROS1, RET, NTRK1/2/3-rearrangements)
 Open to activated sites
Cohort 5: NSCLC patients, currently living in the same home and for at least 2 years prior to NSCLC diagnosis and at any stage of disease, including:

  • Newly diagnosed patients,
  • Patients under treatment for early, locally, or advanced disease
  • Patients under follow-up
  • Survivors (if treatment received within 5 years of inclusion in SPECTA), and
  • presenting a negative test for all previously mentioned molecular alteration (full molecular profile needed)
 Open to activated sites
BACK TO PROJECTS